Immobiliere De Nancy
- Address
- lock Available on a paid plan
Medical Oncology Research at Immobiliere De Nancy
This site in Nancy, France, is focused on medical oncology studies within neoplasms, with research centered on improving outcomes for patients with cancer through better treatment strategies and supportive care.
- High-risk muscle-invasive bladder cancer
- Adjuvant immunotherapy for patients with ctDNA-positive disease after surgery
- Evaluating whether a new anti-PD-L1 therapy can improve disease-free survival
This research aims to test a potential treatment approach that could help reduce the chance of cancer returning after cystectomy in patients with higher-risk disease.
Breast Cancer Supportive Care Studies
Another area of work at Immobiliere De Nancy involves early breast cancer, especially ER positive HER2 negative breast cancer stages I-II, with attention to treatment-related symptoms that affect daily comfort and quality of life.
- Managing endocrine therapy-related musculoskeletal pain
- Improving control of arthralgias, myalgias, and bone pain
- Testing supportive treatments to strengthen quality of life during cancer care
These studies are designed to see whether symptom-focused interventions can make hormonal treatment easier to tolerate for patients with early-stage breast cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 74 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 71 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Immobiliere De Nancy
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 74 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 7 | Unknown | 2019-08-23 | 2024-11-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.